Published in Gene Therapy Weekly, November 9th, 1998
Herlyn's most recent studies focus on the "switch" that turns benign lesions into malignancies. Herlyn said, "This change determines the outcome of disease. By identifying the genes that turn the switch on, we can design new therapies to keep it turned off."
Thus far, two genes, Alphav and Beta3, which are found in the vitronectin receptor (a cell surface glycoprotein that promotes the spread of cells and often is found at sites of skin...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.